ClinicalTrials.gg
RecruitingNCT05448703Updated Oct 6, 2022

A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis

An observational study in Radiation Pneumonitis, sponsored by Huazhong University of Science and Technology. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by Huazhong University of Science and Technology · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Radiation Pneumonitis with a site in China — 9 open to participants now, 11 under way, none of them phase 3. Radiation Pneumonitis · China.

Started
2021
the only one that year
Observational
6 of 16
4 open now
Primary completion
2026-09
later than 6 of 10 live
Registered
7th of 16
by date
Lead sponsor
2 of 16
Huazhong University of Science and Technology

Among the 16 studies in Radiation Pneumonitis with a site in China, this one is the only one that started in 2021, is one of 6 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 7th registered.

Radiation Pneumonitis

40 studies on the registry are indexed under Radiation Pneumonitis; 17 are open to participants now.

Browse Radiation Pneumonitis studies →

Open to participants now

9 of the 16 studies in Radiation Pneumonitis with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Radiation Pneumonitis studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Radiation Pneumonitis with a site in China, or all of them as a file.
02

Study summary

Radiation pneumonitis is the main dose-limiting toxicity of thoracic radiotherapy, which can affect life quality, survival, and the tumor-controlling effects of patients receiving thoracic radiotherapy.

The purpose of this study is to:

  • Identify biomarkers including serum proteins, gene expression, genetic changes, and epigenetic modifications that determine radiation pneumonitis.
  • Investigate the relationship between radiation pneumonitis and other toxicities induced by radiotherapy.
  • Construct a predictive model for radiation pneumonitis.
  • Evaluate survival and treatment outcome of patients with radiation pneumonitis.
Read the detailed description
  1. Collect clinical information, CT images, and peripheral blood of the lung cancer patients treated with thoracic radiotherapy in Tongji Hospital, Hubei Cancer Hospital, and Jingjiang People's Hospital.
  2. Follow up the enrolled patients. All patients enrolled in this study are examined during and one month after radiotherapy. Then, the patients are followed every three months for the first year and every six months thereafter. At each follow-up visits, all patients are asked to undergo a chest CT, and information including survival status, symptoms, CT images, and treatment is collected. Radiation pneumonitis and other toxicities induced by radiotherapy are graded by two radiation oncologists according to the Common Terminology Criteria for Adverse Events 4.0 (CTCAE4.0).
  3. Detect serum proteins, gene expression profile, single-nucleotide polymorphisms, and epigenetic modifications that may be associated with radiation pneumonitis.
  4. Screen biomarkers that are associated with radiation pneumonitis via univariate and multivariate Cox regression analysis.
  5. Construct a predictive model of radiation pneumonitis based on clinical information, radiomics, and biomarkers via machine learning or Least absolute shrinkage and selection operator.
  6. Use Kaplan-Meier and Cox model to analyze the association of radiation pneumonitis with survival and efficacy of antitumor treatment.
  7. Identify biomarkers and predictors of other toxicities induced by radiotherapy including radiation esophagitis, cardiotoxicity and radiodermatitis.
03

Conditions studied

  • Radiation Pneumonitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Lung cancer patients treated with thoracic radiotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of lung cancer by histology
  2. Radiation dose at least 45 Gy
  3. >60
  4. Age>18
  5. of at least 6 months

Exclusion criteria

Exclusion Criteria:

  1. Previous thoracic irradiation
  2. Severe cardiopulmonary diseases
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1

    Lung cancer patients treated with thoracic radiotherapy

    Other: Blood Samples for Biomarkers

Interventions

  • OtherBlood Samples for Biomarkers

    blood sample to be taken at baseline, during radiotherapy, and after radiotherapy

06

What researchers measure

Primary outcomes

  1. Radiation pneumonitis

    radiation pneumonitis grade \>=2 or 3 graded by CTCAE4.0. \[Time Frame: 12 months after radiotherapy\]

    Time frame: 12 months after radiotherapy

  2. Overall Survival

    A long-term follow up will be scheduled to allow a complete survival analysis.

    Time frame: 5 years after radiotherapy

Secondary outcomes

  1. Other injuries induced by radiotherapy

    Assessment of other common injuries induced by thoracic radiotherapy including injuries in heart, skin, and esophagus according to CTCAE4.0.

    Time frame: 5 years after radiotherapy

07

Study locations

3 of 3 sites recruiting
  • Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 43000, China
    Recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
  • Jingjiang People' Hospital
    Jingjiang, Jiangsu 214500, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Sep 2026, 66 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 7, 2022
StartActual
Feb 25, 2021
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Oct 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05448703
Collaborators
Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingjiang People' Hospital
Responsible party
Xianglin Yuan (Professor, Chief Physician, Huazhong University of Science and Technology) — Principal investigator
First posted
Jul 7, 2022
Start date
Feb 25, 2021
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Oct 6, 2022

Study contacts

Xianglin Yuan, PhD
Contact
yuanxianglin@hust.edu.cn
+8613667241722
Lingyan Xiao, MD
Contact
lingyan.xiao123@gmail.com
+8615971474885
Xianglin Yuan, PhD
principal investigator · Tongji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion